Pulse Biosciences, Inc. (PLSE)

Market Cap	1.61B +43.3%
Revenue (ttm)	350,000
Net Income	-72.78M
EPS	-1.08
Shares Out	67.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270,092
Open	23.37
Previous Close	23.40
Day's Range	23.09 - 23.96
52-Week Range	12.56 - 26.30
Beta	1.69
Analysts	Buy
Price Target	22.00 (-7.29%)
Earnings Date	May 7, 2026

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 18, 2016
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PLSE
• Website: https://www.pulsebiosciences.com

Analyst Summary

According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price target is $22.0.

Price Target

$22.0

(-7.29% downside)

Analyst Consensus: Buy